Identifying the specific cells and signaling pathways involved, and verifying them with inhibition of specific signaling molecules, could lead to potential therapeutic targets for diseases characterized by bone loss.
Although higher incorporated AA level contributed to enhanced metabolic activity and biosynthetic capacity of keratocytes grown on cryogel matrices, the presence of excessive amounts of AA molecules could lead to toxic effect and limit cell proliferation and matrix production.
Furthermore, one would expect that a vaccine built with multiple "promiscuous" peptides, capable to bind to several HLA class II molecules could lead to an increased coverage of the genetically heterozygous human population.
The interplay of these molecules could lead to a positive regulatory loop that may further amplify and perpetuate the local inflammatory response in the CB.
Modified derivatives based on initial hits suggest that subsequently derived lead molecules could lead to an HCV-targeted drug, creating a valuable addition to future drug combinations necessary to combat the emergence of resistant HCV.
The rational use of these two molecules could lead to several advantages, such as faster diagnosis, more accurate risk stratification, and optimization of treatment, with consequent benefit to the patient.
